Needham Remains a Buy on OrthoPediatrics (KIDS)


In a report released today, Michael Matson from Needham reiterated a Buy rating on OrthoPediatrics (KIDS), with a price target of $57.00. The company’s shares closed last Thursday at $46.02.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.0% and a 58.9% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.

OrthoPediatrics has an analyst consensus of Strong Buy, with a price target consensus of $56.33, implying a 19.4% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $57.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $55.98 and a one-year low of $32.21. Currently, OrthoPediatrics has an average volume of 153.4K.

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KIDS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts